On 31 May 2023, the European Union and the United States have made important progress towards enabling mutual recognition of inspections of manufacturing facilities of certain veterinary products.
News, activities and interviews from the Veterinary Medicines Division. Published quarterly by the European Medicines Agency.
This regular CTIS newsflash provides key updates on CTIS and links to useful reference materials.
Set for launch later in 2023, the Innovative Devices Access Pathway (IDAP) will be run by the MHRA, NICE, and other partners, including the devolved administrations.
MHRA announces new recognition routes to facilitate safe access to new medicines with seven international partners
Andrew Fisher, Lead Senior GCP Inspector, writes a blog about the recent changes.
CVMP opinions on veterinary medicinal products
This guidance describes FDA’s current recommendations regarding adjusting for covariates in the statistical analysis of randomized clinical trials in drug2 development programs. This guidance provides recommendations for the use of covariates in the analysis of randomized, parallel group clinical trials that are applicable to both superiority trials and noninferiority trials.
As FDA considers the application of its risk-based regulatory framework to the use of AI technologies in drug manufacturing, the Agency has identified in this discussion paper areas for which public feedback would be valuable.
The FDA have published two Guidance Snapshots accompanied by two Guidance Recap Podcasts to highlight the agency’s commitment to improve the diversity of participants in clinical trials, and to increase awareness of the agency’s 2020 guidance, Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs, which presents recommendations sponsors can apply to diversify participation in clinical trials.
Today (24th May) at the World Health Organization (WHO), panelists made an impassioned plea for urgent climate action as it hosted a Strategic Roundtable on the Role of the Health Communities in Climate Action: taking stock and moving forward at the World Health Assembly.
ICH-E6(R3): An Important Global Good Clinical Practice Standards - Available for Public Input.
EMA published its annual report 2022 on 15th May 2023. The report provides an overview of the Agency’s activities to protect and promote public and animal health in the European Union (EU).
The GMDP IWG 3-year workplan is developed with a focus on the Network Strategy and Regulatory Science Strategy (RSS) goals, with a particular emphasis on supply chain integrity and resilience, product quality and the impact of new manufacturing technologies on the supply chain.
This regular CTIS newsflash provides key updates on CTIS and links to useful reference materials.
Edition 169
Highlights from 10 - 12 May 2023 meeting
News, views and interviews for the informed stakeholder. Published four times a year by the European Medicines Agency
EMA has published recommendations for industry on good practices to ensure continuity in the supply of human medicines, prevent shortages and reduce their impact. Medicine shortages are a global health problem and are increasingly affecting European countries. Shortages can lead to medicine rationing and delay in critical treatments, with a significant impact on patient care. In addition, patients may need to use less effective alternatives and face an increased risk of medication errors. Ensuring the availability of authorised medicines in the European Union (EU) is a key priority for EMA and the European medicines regulatory network.
MHRA have updated 'Medical device stand-alone software including apps' to include information on the implementation of new regulations, updates to various links including MORE and new software vigilance guidance.
The World Health Organization (WHO) is calling for caution to be exercised in using artificial intelligence (AI) generated large language model tools (LLMs) to protect and promote human well-being, human safety, and autonomy, and preserve public health.
5 May 2023
Scope, terms of participation and data submission process
EMA has opened a public consultation to review the transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System (CTIS) in the European Union (EU). Stakeholders are invited to send their comments via an online form by midnight (CET) on 28 June 2023.
The newsletter for micro-, small- and medium-sized enterprises (SMEs),
On Friday, the WHO Director General declared an end to the Public Health Emergency of International Concern (PHEIC) for the disease caused by the coronavirus SARS-CoV-2. I welcome this important milestone and would like to share some thoughts about what this means for EMA.
The agency released a new draft guidance that provides recommendations for sponsors, investigators and other stakeholders regarding the implementation of DCTs to advance medical product development and research.
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Q9(R1) Quality Risk Management.”
A write up of the event by Graham Carroll
The E6(R3) overarching principles, Annex 1, Glossary and 3 Appendices will replace the current E6(R2). These are anticipated to reach Step 2 soon and will be available for public consultation.
The government intends to introduce regulations in future that will implement a substantial reform of the current regulatory framework for medical devices in the UK.
The Medicines and Healthcare products Regulatory Agency (MHRA) is committed to making transparency and accountability to the public a fundamental principle of how we do business.
Shiva Ramroop, discusses how we ensure the safety of vaccines for children in the UK.
Clarification of the requirements for the submission of audit reports
Held on 21-22 February 2023 - here is write up of the event.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 18-20 April 2023
This regular CTIS newsflash provides key updates on CTIS and links to useful reference materials.
April 2023 issue of Clinical Trials Highlights.
Key information for patients, consumers and healthcare professionals.
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 April 2023
On 8 December 2022, EMA’s veterinary medicines committee, the CVMP, recommended new measures to reduce the risks from exposure to the excipient N-methyl pyrrolidone (NMP) for women who may handle NMP-containing veterinary medicines and animals that are given these medicines.
EMA has opened a public consultation on a PDF icon reflection paper that discusses key concepts for single-arm clinical trials that are submitted as pivotal evidence in support of marketing authorisation applications for medicines in the European Union (EU).
This guidance provides information on risk-based approaches to monitoring the conduct of clinical investigations of human drug and biological products, medical devices, and combination products.
This version of the guidance replaces the version made available in July 2017. This revision of the guidance document updates hyperlinks, mailing, and contact information.
CDER’s Office of New Drugs (OND) developed a research program in 2018 to centralise and enhance its regulatory science research activities. Recently, the OND Research Program (OND-RP) published its first two fiscal year annual reports
The Access Consortium is offering joint pipeline meetings to pharmaceutical and biotechnology companies.
After almost 8 years as a Board Member, Stephen has decided to step down on 11 July 2023.
Instructions for integrating with the new production MORE platform API.
The World Health Organization (WHO) has appointed five new senior figures to its headquarters leadership team in Geneva.
A collection of frequently asked questions that have been submitted by the industry to the DI taskforce.
LinkedIn Live interview with Peter Arlett: Real-world evidence in medicines regulation, 20 April at 14:00-14:30 CET
Issue 168
View the meeting highlights.
EMA is introducing a number of new features to the PRIority Medicines (PRIME) scheme to strengthen its support for the development of medicines in areas of unmet medical needs.
On 6th April 1948, the United Nations (UN) came together to establish a global organisation that promotes health, keeps the world safe, and serves the vulnerable. Seven decades later, the World Health Organization (WHO) is celebrating its 75th anniversary.
The purpose of this Guide is to illustrate the generally applicable requirements for the design of equipment and to explain how the connection between design and the statement “produced in compliance with GMP” can be made.
Since 2005, the ICH Q9 Guideline on Quality Risk Management has represented the state of the art. A revision was announced at the end of 2020. In January, this revision has reached stage 4 and is now moving into implementation.
DARWIN EU®, the Data Analysis and Real-World Interrogation Network, has accomplished its first year of establishment. Following the set-up of the DARWIN EU® Coordination Centre in February 2022, the first ten data partners were onboarded. The network also initiated its first four studies using real-world data (RWD) from across Europe to better understand diseases, populations and the uses and effects of medicines.
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 21-22 March 2023
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13 - 16 March 2023
MHRA good clinical practice (GCP) metrics reports of compliance issues, 2019-2020
UKRI has published the first edition of its EDI strategy, which outlines our ambition for a thriving research and innovation system, by everyone, for everyone.
EMA has published a report summarising the mid-term achievements of its Regulatory Science Strategy (RSS) to 2025. The report provides an overview of the main deliverables achieved between March 2020 and December 2022 across the human and veterinary areas.
The European Directorate for the Quality of Medicines & HealthCare (EDQM) is seeking input from Certification of suitability (CEP) users for the implementation of the CEP 2.0.
This guideline replaces the 'Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials' (EMA/INS/GCP/454280/2010).
The MHRA and the Department of Health in Northern Ireland, working closely with the HRA, consulted on a set of proposals to update, improve and strengthen the UK legislation that underpins the regulation of clinical trials. Having analysed over 2000 responses received, we will now take forward legislation to reform of the UK clinical trials regulatory framework that will: Ensure patients and their safety are at the focus of all clinical trials and bring the benefits of clinical trials to everyone Create a proportionate and flexible regulatory environment Cement the UK as a destination for international trials Provide a framework that is streamlined, agile and responsive to innovation This package of changes will deliver on our vision for a more proportionate, streamlined, flexible and effective clinical research environment, putting patients at the heart and the UK at the forefront of innovative regulation for clinical trials.
The legislative changes will help to make the UK one of the best countries in the world to conduct clinical research for patients and researchers.
The HRA and the MHRA are committed to enabling the highest quality health and social care research which can benefit the whole UK population. We are working together to help researchers increase the diversity of people taking part in research in the UK and we will set out our expectations in future guidance.
The 115 page ECA Guide was launched and first published at the ECA Live Online Conference GMP-compliant Equipment Design in November 2022 - and can now be downloaded free of charge.
With the aim to enhance communication with the CTIS user community, this regular CTIS newsflash provides key updates on CTIS and links to useful reference materials.
Key information for patients, consumers and healthcare professionals - Published monthly by the European Medicines Agency
FDA issued final guidance.
Update to the Life Sciences Council Joint Statement on Medical Devices Regulatory Reform.
MHRA fees for 2022 - 2023 are remaining the same as 2021 - 2022.
List updated 14 March 2023
List updated 15th March 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) published its Patient Involvement Strategy in October 2021. This defined how we will engage and involve the public and patients in our work.
Blog post by Caroline Barker-Hurden, Posted on 13th March 2023
Large Language Models (LLMs), including ChatGPT and Bard, offer great potential to mimic human conversation. LLMs only directed toward general purposes and whose developers make no claim that the software can be used for a medical purpose are unlikely to qualify as medical devices.
20 - 23 February 2023
With the aim to enhance communication with the CTIS user community, this regular CTIS newsflash provides key updates on CTIS and links to useful reference materials.
February 2023
EMA has published an PDF icon overview of its key recommendations of 2022 regarding the authorisation and safety monitoring of veterinary medicines.
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor, the Commission on Human Medicines
The European Parliament has voted to adopt an extension of the transition period for the EU Medical Device Regulations and to extend the validity of certain device certificates
Date: Tuesday 21 March 2023/Location: Webinar
14-16 February 2023 Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 February 2023
HRA's Make it Public strategy signals an ambition to transform research transparency in the UK.
In October 2022, the Association for the British Pharmaceutical Industry reported that the number of clinical trials run by pharmaceutical companies in the UK had declined over recent years. In October 2022, the Association for the British Pharmaceutical Industry reported that the number of clinical trials run by pharmaceutical companies in the UK had declined over recent years. This wasn’t a case of industry just complaining about how hard it is to run their business. More importantly, they explained the impact this is having on the NHS and all of us as patients. And it’s not good news.
EMA releases highlights from 2022.
6 - 9 February 2023
As of 2 February 2023, EMA’s additional responsibilities regarding the monitoring and mitigation of shortages of critical medical devices during public health emergencies will apply. The new provisions are the last remaining part to be implemented of Regulation (EU) 2022/123, that reinforces EMA’s role in crisis management of critical medicinal products and medical devices during public health emergencies.
Regulators in the European Union (EU) have taken several initiatives in the past four years to increase the efficiency of paediatric regulatory processes and boost the development of medicines for children.
Now Released
Now Released
On 3 February 2023, EMA, the Heads of Medicines Agencies (HMA) and the European Commission (EC) are launching a public consultation on the establishment of a multi-stakeholder platform to improve clinical trials in the European Union (EU). EMA - Public consultation on a multi-stakeholder platform to improve clinical trials in the EU
List of Accredited Phase I Units updated 1 February 2023.
A review and update of the 2016 blog.
The establishment of a regulatory framework for POC manufacturing would bring a range of benefits to patients, healthcare professionals and innovators.
SNOMED International and the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, have signed an agreement governing the creation, maintenance and distribution of a map between both organisations’ terminologies. The agreement came into effect in September 2022.
ICD-11 came into in effect in January 2022 for the national and international recording and reporting of causes of illness, death - and more.
The World Health Organization (WHO) released a new Global Breast Cancer Initiative Framework today providing a roadmap to attain the targets to save 2.5 million lives from breast cancer by 2040.
The WHO Regional Office for the Western Pacific has taken steps to explore the role and potential of dark social communication for promoting health messages and reducing the spread of misleading information during and between influenza pandemics.
Update of the validity period of EMA GMP certificates
EMA - CTIS newsflash released
EMA, the European Commission and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), are closely monitoring and responding to current shortages of antibiotics affecting the EU. Shortages of medicines have been an ongoing public health concern and the situation in the EU has been exacerbated by geopolitical events or trends such as the war in Ukraine, the energy crisis and high inflation rates.
EMA - Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023
EMA - Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 17-18 January 2023
Use of CTIS becomes mandatory for new clinical trial applications in the EU
EMA - update on shortages of antibiotics in the EU EMA's Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) met on Thursday to discuss the progress made and to agree on the next steps in the coordinated response to the ongoing shortages of antibiotic medicines containing amoxicillin (alone and in combination with clavulanic acid) in the EU. The MSSG is made up of representatives from EMA, the European Commission and the Heads of Medicines Agencies (HMA).
Dosage and Administration Section of Labelling for Human Prescription Drug and Biological Products — Content and Format Open for Comment
Open for Comment
The ICH Secretariat is pleased to announce that as of 17 January 2023, the updated ICH E2B(R3) Q&As Version 2.4 for the ICH E2B(R3) Guideline: Electronic Transmission of Individual Case Safety Reports (ICSRs) has reached Step 4 of the ICH Process.
Final version adopted on 18th January 2023.
The ICH M13A draft Guideline presentation available now on the ICH website
The ICH Secretariat is pleased to announce the publication of Module I - Introduction to E2B(R3): Electronic Transmission of Individual Case Safety Reports Training Video.
The ICH Q13 Guideline on Continuous Manufacturing of Drug Substances and Drug Products reached Step 4 of the ICH Process on 16 November 2022. Following the adoption of this Guideline, a Step 4 Introductory Training Presentation has been developed by the Q13 Expert Working Group.
MHRA have made changes made to the Completed paediatric studies guidance text and suggested a new cover letter on their website.
MHRA - Fees Consultation Outcome
MHRA Innovation Office: guidance and support - can provide access to world-class regulatory knowledge, expertise and experience from within the MHRA.
MRC - Motion capture tech could predict disease progression
Adoption and Entry into force of New GDP Guidance Documents
Three years of pandemic learning response: reaching learners across the world with life-saving health knowledge
ICH M10 on bioanalytical method validation - Scientific guideline
A presentations on Annex 1 presented by GMP Inspector Dr Rainer Gnibl is now available (sign up required).
ANSM have released their webinar presentation regarding The implementation of the Clinical Trial Regulation State of play at EU and national level - Future initiatives
EMA - Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 January 2023
CTIS newsflash – 13 January 2023
EMA - Clinical Trials Information System (CTIS) - Sponsor Handbook
EMA - Human Medicines Newsletter, January 23
EMA - SME Newsletter Jan 2023
FDA Draft Guidance for Industry on Statistical Approaches for Assessing Bioequivalence
FDA have signed an Agreement on Mutual Recognition between the Swiss Confederation and the United States of America Relating to Pharmaceutical Good Manufacturing Practice.
MHRA - Horizon Scanning Case Study
MHRA increases UK assessment capacity for in-vitro diagnostic devices
MHRA - Professor Tom Clutton-Brock MBE new Chair of the Interim Devices Working Group
The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published recommendations that aim to facilitate the conduct of decentralised clinical trials (DCTs) while safeguarding the rights and well-being of participants as well as the robustness and reliability of the data collected. This is an outcome of their joint initiative to Accelerate Clinical Trials in the European Union (ACT EU).
The EMA are holding a virtual public CTIS event “CTIS Event on Readiness for mandatory use of the Clinical Trials Regulation from 31 January 2023”.
EMA - Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022
EMA - Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 December 2022
EMA - Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 November - 1 December 2022
The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published recommendations that aim to facilitate the conduct of decentralised clinical trials (DCTs) while safeguarding the rights and well-being of participants as well as the robustness and reliability of the data collected. This is an outcome of their joint initiative to Accelerate Clinical Trials in the European Union (ACT EU).
MHRA assesses its regulatory impact on businesses. Non-qualifying Regulatory Provisions (NQRP) summary 2021-22 available.
MHRA Board Meetings in 2023
MHRA to receive nearly £1m BEIS funding to unlock digital, data and scientific regulatory innovation
Does your organisation provide or utilise Real-World Evidence / Real-World Data for regulatory-grade research? TransCelerate Biopharma Inc.’s Real-World Data (RWD) Audit Readiness Initiative wants to hear from you!
This draft reflection paper provides potential criteria to support the demonstration of a reduction in the antimicrobial or antiparasitic resistance, or an improvement of the benefit-risk balance. Comments should be provided using this template and sent to vet-guidelines@ema.europa.eu by 28 February 2023.
As the regulator, the safety of those volunteering to participate in clinical trials is our first priority, and our oversight of trial conduct is informed by trial sponsors efficiently notifying us of safety issues during the conduct of their trial. This blog aims to clarify regulatory expectations for notification of temporary halts via a substantial amendment and requests to restart a trial after a temporary halt has been notified.